Click Therapeutics Funding, Investors & Competitors

Click Therapeutics has raised $983M across 11 funding rounds, most recently a $50M Series D in April 2026.

Last Click Therapeutics funding round

$50M

Series D · Apr 2026

Cumulative funding Click Therapeutics raised

$983M

across 11 funding rounds

Key investors in Click Therapeutics

  • Sanofi Ventures
  • Hikma Ventures
  • Boehringer Ingelheim
  • Revelation Partners
  • Dassault Systemes
  • Accelmed
  • H.I.G. BioHealth Partners
  • Health Catalyst Capital

Click Therapeutics Overview

About Click Therapeutics

Click Therapeutics is a New York-headquartered developer of prescription digital therapeutics for smoking cessation and major depressive disorder. The platform uses Clickometrics algorithms to personalize cognitive behavioral therapy via app-based modules, with FDA clearance for its smoking program covered by Aetna and Cigna. In phase III trials for depression sponsored by partners like Otsuka, the company enrolls 1,000 patients across 40 U.S. sites. Founded in 2012, it raised $160 million in funding.


Founded

2012

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Click Therapeutics Funding History

Click Therapeutics has raised a total of $983M across 11 funding rounds.

Click Therapeutics' first fundraising round was a $2M seed round in October 2014. The most recent completed round was a $50M Series D in April 2026.

Click Therapeutics funding rounds

Click Therapeutics funding rounds
DateStageInvestorsRaisedDeal Summary
Apr 2026Series DBoehringer Ingelheim (lead)$50M-
Mar 2025Series CDassault Systemes (lead)$49MClick Therapeutics is a New York-based healthcare technology company specializing in prescription digital therapeutics (PDTs) and software-enhanced (SE) drug therapies. Its platform delivers scientifically proven therapies via regulated, clinically validated mobile apps addressing unmet needs in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases, including major depressive disorder, schizophrenia, opioid use disorder, insomnia, episodic migraines, type 2 diabetes, and multiple sclerosis. The company has partnered with major pharma firms like Otsuka (over $300M investment in Rejoyn, FDA-cleared for MDD) and Boehringer Ingelheim ($500M+ deal for schizophrenia digital therapeutic with FDA Breakthrough Device Designation). On March 19, 2025, Dassault Systèmes announced a strategic investment in Click Therapeutics, later detailed as $48.5M in public documents, marking a Series C round. The partnership aims to create unified platforms for digital and pharmaceutical trials, facilitating PDT and SE approvals, expanded labels, and real-world evidence generation. Click Therapeutics gains access to Dassault Systèmes' global network and expertise to accelerate development and deployment of new therapies, responding to FDA guidance on software-enhanced medications. Prior funding includes a $52M Series B in 2021 led by H.I.G. BioHealth Partners and Accelmed Partners, and a $17M round in 2018 led by Sanofi Ventures. The investment supports expansion amid a challenging digital therapeutics market with high-profile failures, positioning Click as a resilient player focused on evidence-based software interventions.
Nov 2024Seed-$3M-
Oct 2021Series BAccelmed (lead); H.I.G. BioHealth Partners (lead); Revelation Partners; K2 HealthVentures; Hikma Ventures; Health Catalyst Capital; Ridgetop Health; Sanofi Ventures$52MClick Therapeutics, a New York-based digital therapeutics company, develops prescription digital therapeutics (DTx) using its proprietary Click Neurobehavioral Intervention (CNI) Platform, which leverages machine learning and data analytics to deliver software-based treatments for conditions like smoking cessation, depression, schizophrenia, chronic pain, migraines, overactive bladder, obesity, cardiometabolic, and autoimmune disorders. The company has partnerships with major pharma firms, including Otsuka for a depression DTx (Rejoyn, FDA-cleared), Boehringer Ingelheim for schizophrenia (over $500M deal with FDA Breakthrough Designation), and earlier with Magellan Health for smoking cessation. On October 22, 2021, Click Therapeutics closed a $52 million Series B financing round co-led by H.I.G. BioHealth Partners and Accelmed Partners II, with participation from Health Catalyst Capital, Revelation Partners, a top biotech hedge fund, and existing investors Sanofi Ventures, K2 HealthVentures, Hikma Ventures, and Ridgetop Health. Alex Zisson from H.I.G. BioHealth and Dr. Uri Geiger from Accelmed joined the board. This followed a $17M round in 2018 led by Sanofi Ventures and $30M debt from K2 in late 2020. Proceeds were allocated to accelerate development and commercialization of its internal DTx pipeline and enhance platform capabilities for personalized treatment predictions. At the time, Click had one marketed product for smoking cessation and was launching a pivotal trial with Otsuka for 540 patients evaluating a depression DTx adjunct to antidepressants. The company continued attracting investment, raising $48.5M in 2025 per public documents, positioning it as a resilient DTx player amid market challenges.
Sep 2020Strategic investmentBoehringer Ingelheim (lead)$500MClick Therapeutics is a prescription digital therapeutics company developing software-based treatments for conditions like schizophrenia, major depressive disorder, opioid use disorder, insomnia, migraines, type 2 diabetes, and multiple sclerosis. On September 11, 2020, it entered a collaboration with Boehringer Ingelheim to co-develop and commercialize CT-155, a mobile app-based digital therapeutic for negative symptoms of schizophrenia built on Click's proprietary platform. Boehringer Ingelheim received exclusive global rights, providing Click Therapeutics with an upfront payment for R&D and additional milestone payments for clinical, regulatory, and commercial achievements totaling over $500 million, plus tiered royalties on net sales. Click Therapeutics leads R&D for CT-155 and supports Boehringer Ingelheim's global commercialization efforts, aiming for FDA and international regulatory authorization as a standalone or adjunct treatment to pharmaceuticals. This partnership leverages Boehringer Ingelheim's expertise in neuropsychiatric clinical development and commercialization to enhance the reach of Click's digital therapeutic software. The deal marks a significant pharma-digital therapeutics alliance, following Click's prior $300 million collaboration with Otsuka in 2019 for a depression treatment and investment from Sanofi Ventures. The company continued raising capital post-2020, including a $52 million Series B in 2021 led by H.I.G. BioHealth Partners and Accelmed Partners, a $48.5 million round in 2025 from Dassault Systèmes, and acquiring Better Therapeutics in 2024 to expand into obesity and cardiometabolic treatments. The Boehringer collaboration expanded in 2022 for additional indications, with CT-155 achieving positive phase 3 results in 2024 and FDA Breakthrough Device Designation.
Dec 2018Undisclosed stageOtsuka Holdings$302MClick Therapeutics collaborated with Otsuka America, Inc. in a January 2019 agreement (announced near the approximate November 2018 date) to develop and commercialize a prescription digital therapeutic (mobile app 'CT-152') for Major Depressive Disorder (MDD), combining Click's software expertise with Otsuka's mental health treatment capabilities. The deal structure involved Otsuka committing to fully fund development, providing up to $10 million in upfront and regulatory milestone payments, approximately $20 million in development funding, and up to $272 million in commercial milestones contingent on regulatory approvals, plus tiered double-digit royalties on global sales. This alliance aimed to address unmet needs in mental healthcare by validating and deploying digital therapeutics alongside traditional therapies. The partnership highlights Click's track record in discovering, validating, and commercially deploying digital prescription treatments. Otsuka's involvement underscores its focus on digital innovation in CNS disorders, positioning the collaboration as a step beyond medication-only solutions.
Oct 2018Series ASanofi Ventures (lead); Hikma Ventures$19MClick Therapeutics develops prescription digital therapeutics using its Click Neurobehavioral Intervention Platform, which leverages machine learning and data analytics to deliver cognitive and neurobehavioral interventions for diseases like smoking cessation, major depressive disorder, insomnia, acute coronary syndrome, and chronic pain. The company's commercial product, Clickotine, is a mobile app for smoking cessation that provides personalized plans, craving management, medication adherence support, and connections to support networks, aligned with U.S. clinical guidelines. In a single-arm study of 416 users, over one-third quit smoking six months after starting. In July 2018, Click Therapeutics closed a $17 million financing round led by Sanofi Ventures, with participation from Hikma Ventures and conversion of recent notes to equity. Sanofi Ventures' Bernard Davitian joined the board, praising Click's platform potential to lead in prescription digital therapeutics and expressing intent to partner across therapeutic areas. The funds supported advancement of the platform and pipeline toward FDA clearance as class II medical devices for physician prescription and payer reimbursement. Prior to the round, Click expanded collaboration with Magellan Health in 2017 for FDA regulatory clearance of indication-specific digital therapies, utilizing Magellan's IP, data, coverage, and reimbursement expertise. The investment positioned Click among emerging digital therapeutic players like Pear Therapeutics and Akili Interactive, amid growing VC interest. Post-round, Click pursued programs like CT-152 for depression and CT-141 for insomnia, with Sanofi viewing early efficacy, engagement, and mechanism of action data as compelling for payer acceptance.
Apr 2017SeedMagellan Health Services (lead)$4M-
Apr 2016Pre-seed-$1M-
Aug 2015SeedFlatiron Investors$2M-
Oct 2014Seed-$2M-

Who has invested in Click Therapeutics?

13 investors have backed Click Therapeutics across its funding rounds, including Sanofi Ventures, Hikma Ventures, Boehringer Ingelheim, Revelation Partners, Dassault Systemes and Accelmed.

Lead investors include Boehringer Ingelheim, Dassault Systemes, Accelmed, H.I.G. BioHealth Partners, Sanofi Ventures and 1 other investor.


Click Therapeutics Investors

Investors in Click Therapeutics by funding rounds participated
InvestorHQRoundsRoleFirst check
Hikma VenturesUnited KingdomLondon2ParticipantOct 2018
Boehringer IngelheimGermanyIngelheim am Rhein2LeadSep 2020
Sanofi VenturesUnited StatesUnited States2LeadOct 2018
Revelation PartnersUnited StatesSan Francisco, CA1ParticipantOct 2021
K2 HealthVenturesUnited StatesBoston, MA1ParticipantOct 2021
Flatiron InvestorsUnited StatesNew York City, NY1ParticipantAug 2015
Otsuka HoldingsJapanJapan1ParticipantDec 2018
AccelmedUnited StatesMiami, FL1LeadOct 2021
Health Catalyst CapitalUnited StatesNew York City, NY1ParticipantOct 2021
Ridgetop HealthUnited StatesPittsburgh, PA1ParticipantOct 2021
Magellan Health ServicesUnited StatesHartford, CT1LeadApr 2017

This data is available for Pro users. Sign up to see all 13 Click Therapeutics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Click Therapeutics

Click Therapeutics has acquired 1 company to date.

Last acquisition by Click Therapeutics was on May 22nd 2024. Click Therapeutics acquired Better Therapeutics for undisclosed valuation.


Latest Acquisitions by Click Therapeutics

Better Therapeutics
Description
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
HQ CountryUnited States
HQ City
-
Deal Date22 May 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Click Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Click Therapeutics Competitors

Click Therapeutics competitors include listed companies like Sphere, Oneview Healthcare, IQVIA and Veeva, and private ones like Hippocratic AI and Overjet.

Public and private companies comparable to Click Therapeutics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Hippocratic AIUnited StatesSan Francisco, CAPrivate--$3.5B-
SphereSouth KoreaSouth KoreaPublicly listed$70M$6M$813M6.9x
OverjetUnited StatesBoston, MAPrivate--$712M-
Oneview HealthcareUnited StatesUnited StatesPublicly listed$14M($12M)$100M7.1x
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
VeevaUnited StatesUnited StatesPublicly listed$3.2B$965M$43B10.2x

Click Therapeutics Public Comps

Click Therapeutics is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, ICON plc, Pro Medicus, United Imaging, Glaukos and M3 Inc..

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Veeva$3.2B$965M11.1x10.2x36.9x22.4x
IDEXX Laboratories$4.3B$1.5B9.5x8.9x27.1x24.9x
Roper Technologies$7.9B$3.2B6.1x5.7x15.2x14.6x
GE HealthCare$21B$3.7B1.8x1.8x10.1x10.0x
ICON plc$8.3B$816M1.9x1.9x19.2x11.3x
Pro Medicus$186M$147M66.6x62.7x84.4x77.6x
United Imaging$2.1B$367M5.5x4.8x30.7x26.9x

This data is available for Pro users. Sign up to see all Click Therapeutics competitors and their valuation data.

Start Free Trial

Common questions about Click Therapeutics

When was Click Therapeutics founded?Click Therapeutics was founded in 2012.
Where is Click Therapeutics headquartered?Click Therapeutics is headquartered in New York City, NY, United States.
Is Click Therapeutics publicly listed?No, Click Therapeutics is a private, VC-backed company.
How much funding has Click Therapeutics raised?Click Therapeutics has raised $983M across 11 funding rounds.
What was Click Therapeutics' last funding round?Click Therapeutics' last funding round was a $50M Series D in April 2026, led by Boehringer Ingelheim.
Who are Click Therapeutics' investors?Click Therapeutics' investors include Hikma Ventures, Boehringer Ingelheim, Sanofi Ventures, Revelation Partners, K2 HealthVentures, Flatiron Investors, Otsuka Holdings, Accelmed, Health Catalyst Capital, Ridgetop Health and 3 others.
Which companies are comparable to Click Therapeutics?Companies comparable to Click Therapeutics include Hippocratic AI, Sphere, Overjet, Oneview Healthcare, IQVIA and Veeva.
How many companies has Click Therapeutics acquired?Click Therapeutics has acquired 1 company, including Better Therapeutics.

See companies similar to Click Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial